| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
161,523 |
147,094 |
$3.91M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
101,966 |
94,708 |
$3.24M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
29,158 |
28,541 |
$2.12M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
53,703 |
51,350 |
$2.10M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
25,862 |
24,710 |
$1.77M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
23,054 |
22,436 |
$1.72M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
14,652 |
14,195 |
$1.16M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
148,592 |
57,793 |
$1.14M |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
14,756 |
14,157 |
$619K |
| 99381 |
|
6,453 |
6,168 |
$439K |
| 99429 |
|
22,643 |
21,810 |
$426K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
5,238 |
5,076 |
$392K |
| 99383 |
|
4,725 |
4,641 |
$387K |
| 99000 |
|
38,852 |
37,333 |
$357K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
30,523 |
29,319 |
$309K |
| 99382 |
|
3,575 |
3,483 |
$290K |
| 90461 |
|
46,361 |
33,445 |
$255K |
| 99384 |
|
2,504 |
2,442 |
$219K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
27,022 |
21,284 |
$214K |
| 92552 |
|
28,965 |
28,292 |
$189K |
| 87634 |
|
8,201 |
5,447 |
$176K |
| 99050 |
|
2,314 |
2,249 |
$170K |
| Q3014 |
Telehealth originating site facility fee |
8,659 |
8,441 |
$166K |
| 87400 |
|
21,488 |
11,115 |
$158K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,616 |
6,260 |
$145K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
5,161 |
4,930 |
$140K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,617 |
2,539 |
$120K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,094 |
1,055 |
$70K |
| 87420 |
|
7,121 |
6,968 |
$69K |
| 83655 |
|
6,085 |
5,974 |
$58K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
693 |
642 |
$49K |
| 99215 |
Prolong outpt/office vis |
539 |
519 |
$39K |
| 99001 |
|
14,663 |
13,924 |
$35K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,486 |
1,436 |
$33K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
109 |
103 |
$33K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
9,712 |
9,270 |
$31K |
| 87807 |
|
3,733 |
3,524 |
$28K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,256 |
1,220 |
$25K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
747 |
700 |
$22K |
| 80050 |
General health panel |
661 |
651 |
$22K |
| 0001A |
|
500 |
498 |
$18K |
| 96160 |
|
9,831 |
9,520 |
$16K |
| 99051 |
|
1,078 |
1,019 |
$15K |
| 0002A |
|
335 |
334 |
$13K |
| 84439 |
|
1,780 |
1,720 |
$12K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,839 |
1,780 |
$10K |
| 80053 |
Comprehensive metabolic panel |
2,791 |
2,706 |
$10K |
| 81003 |
|
5,367 |
5,139 |
$7K |
| 80061 |
Lipid panel |
598 |
579 |
$5K |
| 97169 |
|
245 |
242 |
$5K |
| 87301 |
|
437 |
423 |
$4K |
| 90620 |
|
2,022 |
1,948 |
$4K |
| 90651 |
|
6,622 |
6,451 |
$4K |
| 96161 |
|
3,995 |
3,881 |
$4K |
| 94010 |
|
133 |
131 |
$3K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
335 |
315 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
57 |
57 |
$3K |
| 97803 |
|
471 |
469 |
$3K |
| 87581 |
|
101 |
96 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
255 |
236 |
$3K |
| 0071A |
|
63 |
60 |
$2K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
79 |
77 |
$2K |
| 85027 |
|
875 |
785 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
294 |
244 |
$2K |
| 90473 |
|
219 |
218 |
$1K |
| 90734 |
|
5,268 |
5,140 |
$1K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
42 |
39 |
$923.56 |
| 90686 |
|
13,924 |
13,480 |
$849.94 |
| 82951 |
|
103 |
101 |
$840.58 |
| 90670 |
|
20,689 |
20,149 |
$815.98 |
| 90716 |
|
10,306 |
10,079 |
$743.86 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
56 |
56 |
$700.46 |
| 86308 |
|
179 |
161 |
$697.66 |
| 0081A |
|
12 |
12 |
$484.49 |
| 87070 |
|
114 |
107 |
$426.99 |
| 90707 |
|
10,349 |
10,121 |
$341.54 |
| 36416 |
|
18,204 |
17,106 |
$272.77 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
19 |
19 |
$267.64 |
| 90696 |
|
4,278 |
4,184 |
$249.95 |
| 94375 |
|
14 |
13 |
$241.71 |
| 69210 |
|
18 |
12 |
$210.65 |
| 84030 |
|
2,860 |
2,675 |
$200.60 |
| 94760 |
|
309 |
296 |
$154.44 |
| 97802 |
|
31 |
31 |
$151.30 |
| 90715 |
|
3,443 |
3,350 |
$139.16 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
127 |
113 |
$137.69 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
142 |
120 |
$101.38 |
| 99173 |
|
34,804 |
33,898 |
$96.94 |
| 90680 |
|
8,859 |
8,699 |
$88.96 |
| 90723 |
|
5,607 |
5,366 |
$80.10 |
| 90633 |
|
11,145 |
10,901 |
$72.39 |
| 90648 |
|
10,067 |
9,715 |
$62.54 |
| 90744 |
|
6,581 |
6,454 |
$53.24 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
16 |
15 |
$52.25 |
| 90672 |
|
222 |
221 |
$25.33 |
| 94761 |
|
15 |
13 |
$14.60 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
33,530 |
32,635 |
$11.53 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
16,581 |
15,779 |
$9.15 |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
13,866 |
13,269 |
$5.30 |
| G9716 |
Bmi is documented as being outside of normal parameters, follow-up plan is not completed for documented medical reason |
32,284 |
31,620 |
$4.88 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
108 |
95 |
$0.86 |
| 91300 |
|
722 |
690 |
$0.10 |
| 90681 |
|
3,731 |
3,569 |
$0.05 |
| 90697 |
|
196 |
195 |
$0.05 |
| 90732 |
|
12 |
12 |
$0.04 |
| 90621 |
|
108 |
106 |
$0.02 |
| 90710 |
|
134 |
132 |
$0.01 |
| 90700 |
|
5,249 |
5,121 |
$0.01 |
| 90698 |
|
9,716 |
9,537 |
$0.01 |
| 90713 |
|
274 |
271 |
$0.00 |
| 91308 |
|
55 |
52 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
19 |
17 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
5,061 |
4,900 |
$0.00 |
| 3008F |
|
349 |
341 |
$0.00 |
| 91307 |
|
467 |
396 |
$0.00 |
| 96127 |
|
46 |
28 |
$0.00 |